Overview of screening: where we are and where we may be headed
- PMID: 21709142
- DOI: 10.1093/epirev/mxr006
Overview of screening: where we are and where we may be headed
Abstract
This volume of Epidemiologic Reviews continues a discussion about screening within the evidence community that has been going on for many years. From various perspectives, the authors of these reviews consider the benefits and harms of screening for multiple conditions; the balance between benefits and harms (and costs) is often not clear. With few exceptions, the contribution of screening to improving the health of the public is small, yet it has become a popular and growing form of prevention. It may be that we are learning that the magnitude of benefit from screening is less than we hoped, and the harms may be greater than we thought. Perhaps we should not think of screening as our primary prevention strategy but rather use screening to make a real, but limited contribution to population health for a few conditions. We might target screening to smaller subpopulations with the highest potential benefit and the lowest potential harm. The payoff for population health could be greater if we shifted some resources we now devote to screening to developing, testing, and implementing alternative approaches to preventing the important threats to population health. There needs to be a wider discussion about these issues with the public.
Similar articles
-
The harms of screening: new attention to an old concern.JAMA. 2012 Feb 8;307(6):565-6. doi: 10.1001/jama.2012.100. JAMA. 2012. PMID: 22318274 No abstract available.
-
Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. Preventive services task force.Epidemiol Rev. 2011;33:20-35. doi: 10.1093/epirev/mxr005. Epub 2011 Jun 10. Epidemiol Rev. 2011. PMID: 21666224
-
Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.Health Policy. 2006 Jul;77(2):233-43. doi: 10.1016/j.healthpol.2005.07.014. Epub 2005 Aug 26. Health Policy. 2006. PMID: 16126300
-
Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.J Tissue Viability. 2008 Nov;17(4):115-20. doi: 10.1016/j.jtv.2007.09.005. Epub 2008 Feb 20. J Tissue Viability. 2008. PMID: 19061825 Review.
-
Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.Am J Prev Med. 2009 Apr;36(4):366-75. doi: 10.1016/j.amepre.2009.01.013. Am J Prev Med. 2009. PMID: 19285200 Review.
Cited by
-
How do (false) positively screened patients experience a screening programme for liver cirrhosis or fibrosis in Germany? A qualitative study.Health Expect. 2023 Oct;26(5):1923-1930. doi: 10.1111/hex.13800. Epub 2023 Jun 19. Health Expect. 2023. PMID: 37334867 Free PMC article.
-
Psychometric Properties and Validation of the Italian Version of Ages & Stages Questionnaires Third Edition.Int J Environ Res Public Health. 2023 Mar 12;20(6):5014. doi: 10.3390/ijerph20065014. Int J Environ Res Public Health. 2023. PMID: 36981921 Free PMC article.
-
Psychometric properties of the German version of the Psychological Consequences of Screening Questionnaire (PCQ) for liver diseases.Front Psychol. 2022 Aug 11;13:956674. doi: 10.3389/fpsyg.2022.956674. eCollection 2022. Front Psychol. 2022. PMID: 36033067 Free PMC article.
-
Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.Int J Mol Sci. 2022 May 6;23(9):5213. doi: 10.3390/ijms23095213. Int J Mol Sci. 2022. PMID: 35563604 Free PMC article. Review.
-
Practice guideline: joint CCMG-SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada.J Med Genet. 2018 Apr;55(4):215-221. doi: 10.1136/jmedgenet-2017-105013. Epub 2018 Mar 1. J Med Genet. 2018. PMID: 29496978 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
